These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9468551)

  • 1. Role of urokinase-type plasminogen activator in local immunotherapy.
    Takeda T; Ito Y; Wakasugi E; Kobayashi T; Monden M
    Oncol Rep; 1998; 5(2):329-33. PubMed ID: 9468551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of intratumoral injection of the mixture of OK-432 and fibrinogen (OK/fbg) on gastric cancer].
    Takeda T; Wakasugi T; Katsumoto Y; Sakita I; Nagaoka H; Morimoto H; Tsujinaka T; Monden T; Shiozaki H; Shimano T
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1458-60. PubMed ID: 1530293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intratumoral injection of OK-432 in conjunction with fibrinogen greatly enhances antitumor effect on colorectal carcinomas].
    Monden T; Morimoto H; Murotani M; Yagyu T; Nagaoka H; Shimano T; Mori T
    Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):31-6. PubMed ID: 1707498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages.
    Takeda T; Kobayashi T; Monden T; Katsumoto Y; Ito Y; Wakasugi E; Wakasugi T; Tomita N; Shimano T; Mori T
    Biotherapy; 1993; 7(1):47-54. PubMed ID: 8068483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Local immunotherapy of breast cancer: a case of advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2].
    Fujimori M; Sugenoya A; Kobayashi S; Masuda H; Komatsu M; Takahashi S; Shimizu T; Tsuchiya S; Iida F
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2760-3. PubMed ID: 2551219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Locoregional injection of OK-432/fibrinogen/thrombin for unresectable metastatic liver tumors].
    Yoshida T; Osato H; Sakon M; Monden T; Amano M; Aoki T; Kishimoto S; Umeshita K; Dono K; Gotoh M; Monden M
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1575-7. PubMed ID: 8854809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
    Amano M; Sekimoto M; Monden T; Tomita N; Ohue M; Haba A; Sakita I; Tamaki Y; Monden M
    Dis Colon Rectum; 2000 Mar; 43(3):402-7. PubMed ID: 10733124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin].
    Takekuni K; Sakon M; Kishimoto S; Amano M; Sekimoto M; Aoki T; Oosato H; Dohno K; Umeshita K; Gotoh M; Monden T; Monden M
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1621-3. PubMed ID: 8854822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection].
    Hosokawa T
    Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
    Inuzuka K; Ogata Y; Nagase H; Shirouzu K
    J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.